Late-onset neonatal sepsis (LONS) remains an important threat to the health of preterm neonates in the neonatal intensive care unit. Strategies to optimize care for preterm neonates with LONS are likely to improve survival and long-term neurocognitive outcomes. However, many important questions on how to improve the prevention, early detection, and therapy for LONS in preterm neonates remain unanswered. This review identifies important knowledge gaps in the management of LONS and describe possible methods and technologies that can be used to resolve these knowledge gaps. The availability of computational medicine and hypothesis-free-omics approaches give way to building bedside feedback tools to guide clinicians in personalized management of LONS. Despite advances in technology, implementation in clinical practice is largely lacking although such tools would help clinicians to optimize many aspects of the management of LONS. We outline which steps are needed to get possible research findings implemented on the neonatal intensive care unit and provide a roadmap for future research initiatives.
This review identifies knowledge gaps in prevention, early detection, antibiotic, and additional therapy of late-onset neonatal sepsis in preterm neonates and provides a roadmap for future research efforts.
Research opportunities are addressed, which could provide the means to fill knowledge gaps and the steps that need to be made before possible clinical use.
Methods to personalize medicine and technologies feasible for bedside clinical use are described.
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Stoll, B. J. & Hansen, N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Semin. Perinatol. 27, 293–301 (2003).
Stoll, B. J. et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110, 285–291 (2002).
Lawn, J. E., Wilczynska-Ketende, K. & Cousens, S. N. Estimating the causes of 4 million neonatal deaths in the year 2000. Int. J. Epidemiol. 35, 706–718 (2006).
Shane, A. L., Sanchez, P. J. & Stoll, B. J. Neonatal sepsis. Lancet 390, 1770–1780 (2017).
Stoll, B. J. et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 292, 2357–2365 (2004).
Schlapbach, L. J. et al. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics 128, e348–e357 (2011).
Fleiss, N. et al. Evaluation of the neonatal sequential organ failure assessment and mortality risk in preterm infants with late-onset infection. JAMA Netw. Open 4, e2036518 (2021).
Molloy, E. J. et al. Neonatal sepsis: need for consensus definition, collaboration and core outcomes. Pediatr. Res. 88, 2–4 (2020).
Wynn, J. L. et al. Time for a neonatal-specific consensus definition for sepsis. Pediatr. Crit. Care Med. 15, 523–528 (2014).
Dong, Y. & Speer, C. P. Late-onset neonatal sepsis: recent developments. Arch. Dis. Child Fetal Neonatal Ed. 100, F257–F263 (2015).
Morgan, R. L. et al. Probiotics reduce mortality and morbidity in preterm, low-birth-weight infants: a systematic review and network meta-analysis of randomized trials. Gastroenterology 159, 467–480 (2020).
Rao, S. C. et al. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics 137, e20153684 (2016).
Chi, C. et al. Effects of probiotics in preterm infants: a network meta-analysis. Pediatrics 147, e20200706 (2021).
Schanler, R. J., Shulman, R. J. & Lau, C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 103, 1150–1157 (1999).
de Silva, A., Jones, P. W. & Spencer, S. A. Does human milk reduce infection rates in preterm infants? A systematic review. Arch. Dis. Child Fetal Neonatal Ed. 89, F509–F513 (2004).
Cacho, N. T. & Lawrence, R. M. Innate immunity and breast milk. Front. Immunol. 8, 584 (2017).
Underwood, M. A. Human milk for the premature infant. Pediatr. Clin. North Am. 60, 189–207 (2013).
Cacho, N. T., Parker, L. A. & Neu, J. Necrotizing enterocolitis and human milk feeding: a systematic review. Clin. Perinatol. 44, 49–67 (2017).
Meier, P., Patel, A. & Esquerra-Zwiers, A. Donor human milk update: evidence, mechanisms, and priorities for research and practice. J. Pediatr. 180, 15–21 (2017).
Peila, C. et al. The effect of holder pasteurization on nutrients and biologically-active components in donor human milk: a review. Nutrients 8, 477 (2016).
Daniels, B. et al. The effect of simulated flash-heat pasteurization on immune components of human milk. Nutrients 9, 178 (2017).
Schuller, S. S. et al. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future. Front. Pediatr. 6, 199 (2018).
Quigley, M., Embleton, N. D. & McGuire, W. Formula versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst. Rev. 7, CD002971 (2019).
Maffei, D. et al. Early oral colostrum administration in preterm infants. J. Perinatol. 40, 284–287 (2020).
Rodriguez, N. A., Meier, P. P., Groer, M. W. & Zeller, J. M. Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives. J. Perinatol. 29, 1–7 (2009).
da Cruz Martins, C. et al. Colostrum oropharyngeal immunotherapy for very low birth weight preterm infants: protocol of an intervention study. BMC Pediatr. 20, 371 (2020).
Maertens, K. et al. Breastfeeding after maternal immunisation during pregnancy: providing immunological protection to the newborn: a review. Vaccine 32, 1786–1792 (2014).
Schlaudecker, E. P. et al. IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization. PLoS ONE 8, e70867 (2013).
Cinicola, B. et al. The protective role of maternal immunization in early life. Front. Pediatr. 9, 638871 (2021).
Broad, J. et al. The current state of immunization against Gram-negative bacteria in children: a review of the literature. Curr. Opin. Infect. Dis. 33, 517–529 (2020).
Jakaitis, B. M. & Denning, P. W. Human breast milk and the gastrointestinal innate immune system. Clin. Perinatol. 41, 423–435 (2014).
Manzoni, P. et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 302, 1421–1428 (2009).
Pammi, M. & Suresh, G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst. Rev. 3, CD007137 (2020).
Patel, M. & Kaufman, D. A. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants. Expert Opin. Biol. Ther. 15, 595–600 (2015).
Weisman, L. E. et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128, 271–279 (2011).
Theilacker, C. et al. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J. Infect. Dis. 205, 1076–1085 (2012).
Shah, P. S. & Kaufman, D. A. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst. Rev. CD006449 (2009).
Thammavongsa, V., Kim, H. K., Missiakas, D. & Schneewind, O. Staphylococcal manipulation of host immune responses. Nat. Rev. Microbiol 13, 529–543 (2015).
Malik, P. R. V. & Edginton, A. N. Physiologically-based pharmacokinetic modeling vs. allometric scaling for the prediction of infliximab pharmacokinetics in pediatric patients. CPT Pharmacomet. Syst. Pharm. 8, 835–844 (2019).
Kumar, A. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34, 1589–1596 (2006).
Ng, P. C. Diagnostic markers of infection in neonates. Arch. Dis. Child Fetal Neonatal Ed. 89, F229–F235 (2004).
Ng, P. C. et al. Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch. Dis. Child Fetal Neonatal Ed. 77, F221–F227 (1997).
Chiera, M. et al. Heart rate variability in the perinatal period: a critical and conceptual review. Front. Neurosci. 14, 561186 (2020).
Leon, C., Carrault, G., Pladys, P. & Beuchee, A. Early detection of late onset sepsis in premature infants using visibility graph analysis of heart rate variability. IEEE J. Biomed. Health Inf. 25, 1006–1017 (2021).
Moorman, J. R. et al. Mortality reduction by heart rate characteristic monitoring in very low birth weight neonates: a randomized trial. J. Pediatr. 159, 900–906 e901 (2011).
Fairchild, K. D. et al. Septicemia mortality reduction in neonates in a heart rate characteristics monitoring trial. Pediatr. Res. 74, 570–575 (2013).
Coggins, S. A. et al. Heart rate characteristic index monitoring for bloodstream infection in an NICU: a 3-year experience. Arch. Dis. Child Fetal Neonatal Ed. 101, F329–F332 (2016).
Fairchild, K. D. et al. Vital signs and their cross-correlation in sepsis and NEC: a study of 1,065 very-low-birth-weight infants in two NICUs. Pediatr. Res. 81, 315–321 (2017).
Mithal, L. B. et al. Vital signs analysis algorithm detects inflammatory response in premature infants with late onset sepsis and necrotizing enterocolitis. Early Hum. Dev. 117, 83–89 (2018).
Sullivan, B. A. et al. Clinical and vital sign changes associated with late-onset sepsis in very low birth weight infants at 3 NICUs. J. Neonatal Perinatal Med. https://doi.org/10.3233/NPM-200578 (2021).
Joshi, R. et al. Predicting neonatal sepsis using features of heart rate variability, respiratory characteristics, and ECG-derived estimates of infant motion. IEEE J. Biomed. Health Inf. 24, 681–692 (2020).
Kumar, N. et al. Continuous vital sign analysis for predicting and preventing neonatal diseases in the twenty-first century: big data to the forefront. Pediatr. Res. 87, 210–220 (2020).
Beam, A. L. & Kohane, I. S. Big data and machine learning in health care. JAMA 319, 1317–1318 (2018).
Rajkomar, A., Dean, J. & Kohane, I. Machine learning in medicine. N. Engl. J. Med. 380, 1347–1358 (2019).
Masino, A. J. et al. Machine learning models for early sepsis recognition in the neonatal intensive care unit using readily available electronic health record data. PLoS ONE 14, e0212665 (2019).
Helguera-Repetto, A. C. et al. Neonatal sepsis diagnosis decision-making based on artificial neural networks. Front. Pediatr. 8, 525 (2020).
van de Sande, D. et al. Moving from bytes to bedside: a systematic review on the use of artificial intelligence in the intensive care unit. Intensive Care Med. 47, 750–760 (2021).
Van Laere, D. et al. Machine learning to support hemodynamic intervention in the neonatal intensive care unit. Clin. Perinatol. 47, 435–448 (2020).
Bellini, V., Montomoli, J. & Bignami, E. Poor quality data, privacy, lack of certifications: the lethal triad of new technologies in intensive care. Intensive Care Med, https://doi.org/10.1007/s00134-021-06473-4 (2021).
Delanghe, J. R. & Speeckaert, M. M. Translational research and biomarkers in neonatal sepsis. Clin. Chim. Acta 451, 46–64 (2015).
Sharma, D., Farahbakhsh, N., Shastri, S. & Sharma, P. Biomarkers for diagnosis of neonatal sepsis: a literature review. J. Matern Fetal Neonatal Med. 31, 1646–1659 (2018).
Iroh Tam, P. Y. & Bendel, C. M. Diagnostics for neonatal sepsis: current approaches and future directions. Pediatr. Res. 82, 574–583 (2017).
Kuster, H. et al. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet 352, 1271–1277 (1998).
Arnon, S. et al. Serum amyloid A: an early and accurate marker of neonatal early-onset sepsis. J. Perinatol. 27, 297–302 (2007).
Ho, J. et al. Pathological role and diagnostic value of endogenous host defense peptides in adult and neonatal sepsis: a systematic review. Shock 47, 673–679 (2017).
Bellos, I. et al. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. Eur. J. Pediatr. 177, 625–632 (2018).
Bhandari, V. Effective biomarkers for diagnosis of neonatal sepsis. J. Pediatr. Infect. Dis. Soc. 3, 234–245 (2014).
Ludwig, K. R. & Hummon, A. B. Mass spectrometry for the discovery of biomarkers of sepsis. Mol. Biosyst. 13, 648–664 (2017).
Ng, S. et al. Precision medicine for neonatal sepsis. Front. Mol. Biosci. 5, 70 (2018).
Cao, Z. & Robinson, R. A. The role of proteomics in understanding biological mechanisms of sepsis. Proteom. Clin. Appl. 8, 35–52 (2014).
Schmerler, D. et al. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J. Lipid Res. 53, 1369–1375 (2012).
Stewart, C. J. et al. Metabolomic and proteomic analysis of serum from preterm infants with necrotising entercolitis and late-onset sepsis. Pediatr. Res. 79, 425 (2015).
Kim, D. et al. Pilot application of magnetic nanoparticle-based biosensor for necrotizing enterocolitis. J Proteomics Bioinformatics, Suppl 5:002 (2015).
Ng, P. C. et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J. Clin. Invest. 120, 2989–3000 (2010).
Buhimschi, C. S. et al. Proteomics mapping of cord blood identifies haptoglobin “switch-on” pattern as biomarker of early-onset neonatal sepsis in preterm newborns. PLoS ONE 6, e26111 (2011).
Mardegan, V. et al. Untargeted and targeted metabolomic profiling of preterm newborns with early onset sepsis: a case-control study. Metabolites 11, 115 (2021).
Dessi, A. et al. Monitoring neonatal fungal infection with metabolomics. J. Matern. Fetal Neonatal Med. 27(Suppl. 2), 34–38 (2014).
Sarafidis, K. et al. Urine metabolomics in neonates with late-onset sepsis in a case-control study. Sci. Rep. 7, 1–9 (2017).
Fanos, V. et al. Urinary 1H-NMR and GC-MS metabolomics predicts early and late onset neonatal sepsis. Early Hum. Dev. 90, S78–S83 (2014).
Mickiewicz, B., Vogel, H. J., Wong, H. R. & Winston, B. W. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am. J. Respir. Crit. Care Med. 187, 967–976 (2013).
Ou, H. et al. Expression of microRNA-23b in patients with sepsis and its effect on leukocytes and the expression of E-selectin and ICAM-1. Exp. Ther. Med. 16, 4707–4711 (2018).
Fatmi, A. et al. miRNA-23b as a biomarker of culture-positive neonatal sepsis. Mol. Med. 26, 94 (2020).
Sweeney, T. E. et al. Validation of the sepsis metascore for diagnosis of neonatal sepsis. J. Pediatr. Infect. Dis. Soc. 7, 129–135 (2018).
Tebani, A., Afonso, C., Marret, S. & Bekri, S. Omics-based strategies in precision medicine: toward a paradigm shift in inborn errors of metabolism investigations. Int. J. Mol. Sci. 17, 1555 (2016).
Nagana Gowda, G. A. & Raftery, D. Biomarker discovery and translation in metabolomics. Curr. Metabolomics 1, 227–240 (2013).
Buchegger, P., Sauer, U., Toth-Szekely, H. & Preininger, C. Miniaturized protein microarray with internal calibration as point-of-care device for diagnosis of neonatal sepsis. Sensors (Basel) 12, 1494–1508 (2012).
Tighe, P. J., Ryder, R. R., Todd, I. & Fairclough, L. C. ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin. Appl. 9, 406–422 (2015).
Waelgaard, L., Pharo, A., Tonnessen, T. I. & Mollnes, T. E. Microdialysis for monitoring inflammation: efficient recovery of cytokines and anaphylotoxins provided optimal catheter pore size and fluid velocity conditions. Scand. J. Immunol. 64, 345–352 (2006).
Pammi, M. et al. Microbiome signatures in neonatal central line associated bloodstream infections. PLoS ONE 15, e0227967 (2020).
Berkhout, D. J. C. et al. Late-onset sepsis in preterm infants can be detected preclinically by fecal volatile organic compound analysis: a prospective, multicenter cohort study. Clin. Infect. Dis. 68, 70–77 (2019).
Gofin, Y. et al. Salivary C-reactive protein—a possible predictor of serum levels in pediatric acute respiratory illness. Eur. J. Pediatr, 180, 2465–2472 (2021).
El Manouni El Hassani, S. et al. Profound pathogen-specific alterations in intestinal microbiota composition precede late onset sepsis in preterm infants: a longitudinal multicenter case-control study. Clin. Infect. Dis. 73, e224–e232(2021).
van Donge, T., Bielicki, J. A., van den Anker, J. & Pfister, M. Key components for antibiotic dose optimization of sepsis in neonates and infants. Front Pediatr. 6, 325 (2018).
Stockmann, C. et al. Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatr. Drugs 16, 67–81 (2014).
Kuppala, V. S., Meinzen-Derr, J., Morrow, A. L. & Schibler, K. R. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J. Pediatr. 159, 720–725 (2011).
Tsai, M. H. et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics 133, e322–e329 (2014).
Verroken, A. et al. Clinical impact of MALDI-TOF MS identification and rapid susceptibility testing on adequate antimicrobial treatment in sepsis with positive blood cultures. PLoS ONE 11, e0156299 (2016).
Connell, T. G. et al. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children’s hospital. Pediatrics 119, 891–896 (2007).
Jardine, L., Davies, M. W. & Faoagali, J. Incubation time required for neonatal blood cultures to become positive. J. Paediatr. Child Health 42, 797–802 (2006).
Brodská, H. et al. Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin. Exp. Med. 13, 165–170 (2013).
Thomas-Rüddel, D. O. et al. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. Crit. Care 22, 128 (2018).
Bassetti, M. et al. Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. Expert Rev. Anti Infective Ther. 17, 99–105 (2019).
Nakajima, A. et al. Clinical utility of procalcitonin as a marker of sepsis: a potential predictor of causative pathogens. Intern. Med. 53, 1497–1503 (2014).
Clish, C. B. Metabolomics: an emerging but powerful tool for precision medicine. Mol. Case Stud. 1, a000588 (2015).
Dessì, A. et al. New diagnostic possibilities in systemic neonatal infections: metabolomics. Early Hum. Dev. 90, S19–S21 (2014).
Eckerle, M. et al. Metabolomics as a driver in advancing precision medicine in sepsis. Pharmacotherapy 37, 1023–1032 (2017).
McShane, L. M. et al. Criteria for the use of omics-based predictors in clinical trials. Nature 502, 317–320 (2013).
Laughon, M. M. et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev. Clin. Pharmacol. 4, 643–652 (2011).
Rivera-Chaparro, N. D., Cohen-Wolkowiez, M. & Greenberg, R. G. Dosing antibiotics in neonates: review of the pharmacokinetic data. Future Microbiol. 12, 1001–1016 (2017).
Flint, R. B. et al. Large differences in neonatal drug use between NICUs are common practice: time for consensus? Br. J. Clin. Pharmacol. 84, 1313–1323 (2018).
Blot, S. I., Pea, F. & Lipman, J. The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv. Drug Deliv. Rev. 77, 3–11 (2014).
Tremoulet, A. et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob. Agents Chemother. 58, 3013–3020 (2014).
Allegaert, K., Mian, P. & van den Anker, J. N. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr. Pharmacol. Des. 23, 5769–5778 (2017).
Voller, S. et al. Model-based clinical dose optimization for phenobarbital in neonates: an illustration of the importance of data sharing and external validation. Eur. J. Pharmacol. Sci. 109S, S90–S97 (2017).
Mould, D. R. Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin. Pharmacol. Ther. 92, 283–286 (2012).
Holford, N. H., Kimko, H. C., Monteleone, J. P. & Peck, C. C. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40, 209–234 (2000).
Mueller, M., de la Pena, A. & Derendorf, H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48, 369–377 (2004).
Nielsen, L. E. et al. One size fits all? Application of susceptible-dose-dependent breakpoints to pediatric patients and laboratory reporting. J. Clin. Microbiol. 58, e01446–19 (2019).
Kearns, G. L. et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157–1167 (2003).
Liu, C. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52, 285–292 (2011).
Stockmann, C. et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. Infect. Dis. Ther. 4, 187–198 (2015).
Allegaert, K., Flint, R. & Smits, A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin. Drug Metab. Toxicol. 15, 735–749 (2019).
Abdulla, A. et al. Model-informed precision dosing of antibiotics in pediatric patients: a narrative review. Front Pediatr. 9, 624639 (2021).
Mian, P. et al. Therapeutic drug monitoring in neonates: what makes them unique? Curr. Pharmacol. Des. 23, 5790–5800 (2017).
Jansen, S. J. et al. Benzylpenicillin serum concentrations in neonates with group B Streptococci sepsis or meningitis: a descriptive cohort study. Pediatr. Infect. Dis. J. 40, 434–439 (2021).
Ng, P. C., Ma, T. P. & Lam, H. S. The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis. Arch. Dis. Child Fetal Neonatal Ed. 100, F448–F452 (2015).
de Boode, W.-P. Clinical monitoring of systemic hemodynamics in critically ill newborns. Early Hum. Dev. 86, 137–141 (2010).
Tibby, S. M., Hatherill, M., Marsh, M. J. & Murdoch, I. A. Clinicians’ abilities to estimate cardiac index in ventilated children and infants. Arch. Dis. Child. 77, 516–518 (1997).
de Boode, W. P. et al. The role of neonatologist performed echocardiography in the assessment and management of neonatal shock. Pediatr. Res. 84, 57–67 (2018).
De Boode, W. P. et al. Recommendations for neonatologist performed echocardiography in Europe: consensus statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatr. Res. 80, 465–471 (2016).
da Costa, C. S., Greisen, G. & Austin, T. Is near-infrared spectroscopy clinically useful in the preterm infant? Arch. Dis. Child.-Fetal Neonatal Ed. 100, F558–F561 (2015).
Liem, K. D. & Greisen, G. Monitoring of cerebral haemodynamics in newborn infants. Early Hum. Dev. 86, 155–158 (2010).
Sood, B. G., McLaughlin, K. & Cortez, J. Near-infrared spectroscopy: applications in neonates. Semin. Fetal Neonatal Med. 164–172 (2015).
van der Laan, M. E. et al. Multisite tissue oxygenation monitoring indicates organ-specific flow distribution and oxygen delivery related to low cardiac output in preterm infants with clinical sepsis. Pediatr. Crit. Care Med. 17, 764–771 (2016).
Wynn, J. L., Neu, J., Moldawer, L. L. & Levy, O. Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J. Perinatol. 29, 79–88 (2009).
Dowling, D. J. & Levy, O. Ontogeny of early life immunity. Trends Immunol. 35, 299–310 (2014).
Olin, A. et al. Stereotypic immune system development in newborn children. Cell 174, 1277–1292 e1214 (2018).
Melville, J. M. & Moss, T. J. The immune consequences of preterm birth. Front. Neurosci. 7, 79 (2013).
Kollmann, T. R., Levy, O., Montgomery, R. R. & Goriely, S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 37, 771–783 (2012).
Basha, S., Surendran, N. & Pichichero, M. Immune responses in neonates. Expert Rev. Clin. Immunol. 10, 1171–1184 (2014).
Hibbert, J. E., Currie, A. & Strunk, T. Sepsis-induced immunosuppression in neonates. Front. Pediatr. 6, 357 (2018).
Karlsson, H., Hessle, C. & Rudin, A. Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect. Immun. 70, 6688–6696 (2002).
Aulin, L. B. S. et al. Biomarker-guided individualization of antibiotic therapy. Clin. Pharmacol. Ther. 110, 346–360 (2021).
Keij, F. M. et al. Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis. J. Clin. Transl. Sci. 18, e140 (2021).
Buras, J. A., Holzmann, B. & Sitkovsky, M. Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4, 854–865 (2005).
Meeker, N. D. & Trede, N. S. Immunology and zebrafish: spawning new models of human disease. Dev. Comp. Immunol. 32, 745–757 (2008).
Bauer, M. et al. A transcriptomic biomarker to quantify systemic inflammation in sepsis—a prospective multicenter phase II diagnostic study. EBioMedicine 6, 114–125 (2016).
Kurul, S. et al. Association of inflammatory biomarkers with subsequent clinical course in suspected late onset sepsis in preterm neonates. Crit. Care 25, 12 (2021).
Pammi, M. & Weisman, L. E. Late-onset sepsis in preterm infants: update on strategies for therapy and prevention. Expert Rev. Anti Infect. Ther. 13, 487–504 (2015).
Ohlsson, A. & Lacy, J. B. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst. Rev. 1, CD001239 (2020).
Haque, K. N., Remo, C. & Bahakim, H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin. Exp. Immunol. 101, 328–333 (1995).
Carr, R., Modi, N. & Dore, C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst. Rev. CD003066 (2003).
Castagnola, E. & Dufour, C. Role of G-CSF GM-CSF in the management of infections in preterm newborns: an update. Early Hum. Dev. 90(Suppl 2), S15–S17 (2014).
Opal, S. M. New perspectives on immunomodulatory therapy for bacteraemia and sepsis. Int J. Antimicrob. Agents 36(Suppl. 2), S70–S73 (2010).
Ward, A. & Clissold, S. P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34, 50–97 (1987).
Neuner, P. et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83, 262–267 (1994).
Lauterbach, R. & Zembala, M. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur. J. Pediatr. 155, 404–409 (1996).
Szymura-Oleksiak, J., Bury, J., Lauterbach, R. & Pawloski, M. Serum concentrations of pentoxifylline and its metabolites in premature infants with sepsis when administered by continuous intravenous infusion. Pharmaceut. Sci. 3, 367–371 (1997).
Mandell, G. L. Cytokines, phagocytes, and pentoxifylline. J. Cardiovasc. Pharmacol. 25(Suppl 2), S20–S22 (1995).
Windmeier, C. & Gressner, A. M. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen. Pharmacol. 29, 181–196 (1997).
Schroer, R. H. Antithrombotic potential of pentoxifylline. A hemorheologically active drug. Angiology 36, 387–398 (1985).
Yang, S. et al. Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G1274–G1281 (2000).
Danjo, W., Fujimura, N. & Ujike, Y. Effect of pentoxifylline on diaphragmatic contractility in septic rats. Acta Med Okayama 62, 101–107 (2008).
Pammi, M. & Haque, K. N. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst. Rev. CD004205 (2015).
Salman, S. et al. Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. Br. J. Clin. Pharmacol. 85, 147–159 (2019).
Lalu, M. M. et al. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. Elife 5, e17850 (2016).
Johnson, C. L., Soeder, Y. & Dahlke, M. H. Concise review: mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes. Stem Cells Transl. Med. 6, 1141–1151 (2017).
Laroye, C., Gibot, S., Reppel, L. & Bensoussan, D. Concise review: mesenchymal stromal/stem cells: a new treatment for sepsis and septic shock? Stem Cells 35, 2331–2339 (2017).
Liau, L. L. et al. The potential of mesenchymal stromal cell as therapy in neonatal diseases. Front Pediatr. 8, 591693 (2020).
McIntyre, L. A. et al. Cellular immunotherapy for septic shock. A phase I clinical trial. Am. J. Respir. Crit. Care Med. 197, 337–347 (2018).
Sato, Y. et al. Prophylactic therapy with human amniotic fluid stem cells improved survival in a rat model of lipopolysaccharide-induced neonatal sepsis through immunomodulation via aggregates with peritoneal macrophages. Stem Cell Res. Ther. 11, 300 (2020).
Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138–150 (2003).
Zhao, J. et al. Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc. Natl Acad. Sci. USA 105, 7528–7533 (2008).
Wynn, J. L. et al. The influence of developmental age on the early transcriptomic response of children with septic shock. Mol. Med. 17, 1146–1156 (2011).
Wynn, J. L. et al. Postnatal age is a critical determinant of the neonatal host response to sepsis. Mol. Med. 21, 496–504 (2015).
Schüller, S. S. et al. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future. Front. Pediatr. 6, 199 (2018).
Ridings, P. C. et al. Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established. Arch. Surg. 129, 1144–1152 (1994).
Itenov, T. S., Murray, D. D. & Jensen, J. U. S. Sepsis: personalized medicine utilizing ‘omic’ technologies—a paradigm shift? Healthcare (Basel) 6, 111 (2018).
van Karnebeek, C. D. M. et al. The role of the clinician in the multi-omics era: are you ready? J. Inherit. Metab. Dis. 41, 571–582 (2018).
Agakidou, E., Agakidis, C., Gika, H. & Sarafidis, K. Emerging biomarkers for prediction and early diagnosis of necrotizing enterocolitis in the era of metabolomics and proteomics. Front. Pediatr. 8, 602255 (2020).
The authors declare no competing interests.
No patient consent was required.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kurul, S., Fiebig, K., Flint, R.B. et al. Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research. Pediatr Res (2021). https://doi.org/10.1038/s41390-021-01721-1